Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8349793 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TDP1GPR35L3MBTL1LMNA | |
| SCHEMBL68284 | 0.85 | TDP1 (0.53) | ALDH1A1TDP1GPR35L3MBTL1LMNA | |
| SCHEMBL4466194 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TDP1L3MBTL1LMNAKDM4E | |
| SCHEMBL31077739 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TDP1L3MBTL1LMNAKDM4E | |
| SCHEMBL7696511 | 0.82 | TDP1 (0.50) | ALDH1A1TDP1GPR35L3MBTL1LMNA | |
| SCHEMBL6816142 | 0.81 | G6PD (0.51) | ALDH1A1TDP1GPR35L3MBTL1LMNA | |
| SCHEMBL2545076 | 0.81 | ALDH1A1 (0.49) | ALDH1A1TDP1GPR35L3MBTL1LMNA | |
| SCHEMBL19435537 | 0.81 | TDP1 (0.49) | ALDH1A1TDP1GPR35L3MBTL1LMNA | |
| SCHEMBL6973058 | 0.80 | ALDH1A1 (0.52) | ALDH1A1TDP1L3MBTL1LMNAKDM4E | |
| SCHEMBL15018462 | 0.80 | ALDH1A1 (0.52) | ALDH1A1TDP1L3MBTL1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162871-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2021-12-16 | — | — | US | disclosed |
| EP-3856176-A2 | INHIBITORS OF VAP-1 | Acucela Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-113164454-A | Inhibitors of VAP-1 | 奥克塞拉有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020069330-A2 | INHIBITORS OF VAP-1 | ACUCELA INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2007134328-A2 | GELDANAMYCINS AND THEIR QUINONE MOIETIES INHIBIT CANCER BY ACTING ON MITOCHONDRIAL VOLTAGE-DEPENDENT ANION CHANNEL (VDAC) PROTEIN | VAN ANDEL RESEARCH INSTITUTE (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-0867432-B1 | Fused N-heterocyclic compounds substituted with benzyloxy, process for their preparation and their use as bradykinin receptor antagonists | AVENTIS PHARMA GMBH (DE) | 2004-06-09 | — | — | EP | disclosed |
| US-6211196-B1 | 8-BENZYLOXY-(TETRAHYDRO)QUINOLINE DERIVATIVES; LIVER CIRRHOSIS, ALZHEIMER*S DISEASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-04-03 | — | — | US | disclosed |
| EP-0867432-A2 | Fused N-heterocyclic compounds substituted with benzyloxy, process for their preparation and their use as bradykinin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787791-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | ALDH1A1 869/4885TDP1 215/4885GPR35 4690/4885 |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | ALDH1A1 869/4885TDP1 215/4885GPR35 4690/4885 |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | ALDH1A1 869/4885TDP1 215/4885GPR35 4690/4885 |
| US-12162871-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | ALDH1A1 869/4885TDP1 215/4885GPR35 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.